Switch theme
Sign up to access all valuation multiples
Oncoinvent ASA is a Norwegian clinical-stage biotech company focusing on cancer care through direct alpha therapy. It focuses on a technology platform that uses radionuclides to deliver powerful alpha radiation directly to cancer cells, killing them by causing irreparable DNA damage. The company's main product candidate, Radspherin, is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities.
2010
34
LTM Revenue $0.8M
LTM EBITDA -$12.5M
$4.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oncoinvent has a last 12-month revenue (LTM) of $0.8M and a last 12-month EBITDA of -$12.5M.
In the most recent fiscal year, Oncoinvent achieved revenue of $0.3M and an EBITDA of -$12.5M.
Oncoinvent expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oncoinvent valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.8M | XXX | $0.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | -$0.9M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | -341% | XXX | XXX | XXX |
| EBITDA | -$12.5M | XXX | -$12.5M | XXX | XXX | XXX |
| EBITDA Margin | -1575% | XXX | -4603% | XXX | XXX | XXX |
| EBIT | -$14.0M | XXX | -$14.0M | XXX | XXX | XXX |
| EBIT Margin | -1762% | XXX | -5169% | XXX | XXX | XXX |
| Net Profit | -$13.9M | XXX | -$13.9M | XXX | XXX | XXX |
| Net Margin | -1750% | XXX | -5139% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Oncoinvent's stock price is NOK 2 (or $0).
Oncoinvent has current market cap of NOK 176M (or $17.4M), and EV of NOK 49.7M (or $4.9M).
See Oncoinvent trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.9M | $17.4M | XXX | XXX | XXX | XXX | $-0.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Oncoinvent has market cap of $17.4M and EV of $4.9M.
Oncoinvent's trades at 18.2x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Oncoinvent's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncoinvent has a P/E ratio of -1.3x.
See valuation multiples for Oncoinvent and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17.4M | XXX | $17.4M | XXX | XXX | XXX |
| EV (current) | $4.9M | XXX | $4.9M | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 18.2x | XXX | XXX | XXX |
| EV/EBITDA | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOncoinvent's revenue per employee in the last FY averaged $8K, while opex per employee averaged $0.4M for the same period.
Oncoinvent's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncoinvent's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oncoinvent and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1575% | XXX | -4603% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $8K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1465% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4828% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncoinvent acquired XXX companies to date.
Last acquisition by Oncoinvent was XXXXXXXX, XXXXX XXXXX XXXXXX . Oncoinvent acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oncoinvent founded? | Oncoinvent was founded in 2010. |
| Where is Oncoinvent headquartered? | Oncoinvent is headquartered in Norway. |
| How many employees does Oncoinvent have? | As of today, Oncoinvent has 34 employees. |
| Is Oncoinvent publicy listed? | Yes, Oncoinvent is a public company listed on OSL. |
| What is the stock symbol of Oncoinvent? | Oncoinvent trades under ONCIN ticker. |
| When did Oncoinvent go public? | Oncoinvent went public in 2024. |
| Who are competitors of Oncoinvent? | Similar companies to Oncoinvent include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Oncoinvent? | Oncoinvent's current market cap is $17.4M |
| What is the current revenue of Oncoinvent? | Oncoinvent's last 12 months revenue is $0.8M. |
| What is the current EV/Revenue multiple of Oncoinvent? | Current revenue multiple of Oncoinvent is 6.2x. |
| Is Oncoinvent profitable? | Yes, Oncoinvent is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oncoinvent? | Oncoinvent's last 12 months EBITDA is -$12.5M. |
| What is Oncoinvent's EBITDA margin? | Oncoinvent's last 12 months EBITDA margin is -1575%. |
| What is the current EV/EBITDA multiple of Oncoinvent? | Current EBITDA multiple of Oncoinvent is -0.4x. |
| What is the current FCF of Oncoinvent? | Oncoinvent's last 12 months FCF is -$8.8M. |
| What is Oncoinvent's FCF margin? | Oncoinvent's last 12 months FCF margin is -1112%. |
| What is the current EV/FCF multiple of Oncoinvent? | Current FCF multiple of Oncoinvent is -0.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
